Allergan Adds a New Wrinkle to Anti-Aging Market

Allergan, Inc., Irvine, CA, the maker of Botox Cosmetic (Botulinum Toxin Type A), today announced it is launching its ‘next-generation’ hyaluronic acid dermal filler products, Juvederm Ultra and Juvederm Ultra Plus, through an experience trial involving a group of physicians with expertise in facial aesthetics, in advance of nationwide product availability in January 2007. Allergan will begin accepting physician pre-orders for the products on November 1, 2006 via its nationwide sales force.

“We are pleased to announce the availability of Juvederm Ultra and Juvederm Ultra Plus as they join Botox Cosmetic and our physician-dispensed skin care treatments in Allergan’s facial aesthetics portfolio,” said Robert Grant, Allergan corporate vice president and president of Inamed, a division of Allergan. “We believe the unique scientific benefits of Juvederm, along with its technologically advanced smooth formulation will establish the brand as a leader alongside Botox Cosmetic in Allergan’s Total Facial Rejuvenation offering.”

The Juvederm experience trial is a multi-center, open-label trial, designed to gain relevant information on physicians’ use of Juvederm and Juvederm Ultra Plus and evaluate the persistence of and patient satisfaction with the products in daily clinical practice.

“Many physicians have been awaiting the availability of the Juvederm family of dermal fillers,” continued Mr. Grant. “As a market leader devoted to the Science of Facial Aesthetics, it is our responsibility to provide our customers with the appropriate scientific and clinical information on the product to ensure optimal patient outcomes.”